Loading clinical trials...
Loading clinical trials...
An Open-label, Phase 1 Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Brensocatib in Subjects With Normal Hepatic Function and Subjects With Hepatic Impairment
Conditions
Interventions
Brensocatib
Locations
3
United States
USA002
Rialto, California, United States
USA003
Orlando, Florida, United States
USA001
San Antonio, Texas, United States
Start Date
October 4, 2022
Primary Completion Date
June 1, 2023
Completion Date
June 1, 2023
Last Updated
July 19, 2023
NCT07324616
NCT04271488
NCT06952634
NCT06841315
NCT06619054
NCT06813781
Lead Sponsor
Insmed Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions